Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis

Baniandrés-Rodríguez, OfeliaFerran Farrés, MartaGarcía-Doval, IgnacioBiobadaderm Study Group2022-02-222022-02-222021Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis. J Am Acad Dermatol. 2021 Feb; 84(2): 513-7. DOI: 10.1016/j.jaad.2020.10.0460190-9622http://hdl.handle.net/10230/52538application/pdfeng© Elsevier http://dx.doi.org/10.1016/j.jaad.2020.10.046COVID-19 (Malaltia)Psoriasi -- TractamentIncidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysisinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1016/j.jaad.2020.10.046info:eu-repo/semantics/openAccess